An interventional study of The Motivational Interviewing Technique in Pediatric ALL, sponsored by Izmir Katip Celebi University. Enrolling by invitation at 1 site in Turkey. Open to participants aged 12 Years to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-14.
Sponsored by Izmir Katip Celebi University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Turkey — 6 open to participants now, 11 under way, 5 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Turkey.
Among the 38 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Turkey, this one is the 20th largest by planned enrollment of the 31 interventional ones that give a count, is one of 6 that started in 2023, is one of 15 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 29th registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →6 of the 38 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Turkey are open now. Recruiting first, the newest first:
Ege University · Sites in Turkey
Ages 4–12
Ascentage Pharma Group Inc. · Sites in Turkey, United States, Australia and 9 more countries
Ages 18+
St. Anna Kinderkrebsforschung · Sites in Turkey, Argentina, Australia and 28 more countries
Ages 1 mo–18 yrs
Fenerbahce University · Sites in Turkey
Ages 8–14 · Healthy volunteers
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 12–18
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 12 Years to 15 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 11 · Phase 4 1
First in 1995; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is above the median of 40 across 1,953 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 102 across the 31 interventional studies, 83 across the 7 observational. Of the 24 that completed or were terminated, 4 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 38 have an industry lead sponsor. The 10 most frequent:
Izmir Katip Celebi University is the lead sponsor of 198 studies on the registry; 39 are open to participants now.
Izmir Katip Celebi University has 1 study filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
2 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04521231AmgenA Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL | 2027-11-24 |
Add all 2 to your calendar (.ics) → With an account.
Among the 38 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Epilepsy is the most common serious neurodevelopmental disorder of childhood characterized by recurrent seizures, affecting approximately 0.9% of children and adolescents worldwide. Although epileptic seizures are an important element of epilepsy in children, there are many neurological, mental health and cognitive comorbidities in childhood epilepsy that increase the burden of the disease and cause a decrease in quality of life. Motivational interviewing has been found to have a positive effect on the treatment and prevention of chronic diseases; It is a patient-centered counseling that explores, strengthens, and directs the individual's motivation for change.
Adolescence period; It is an important stage of development in which the self-concept develops, self-related schemas are created and carried into adulthood. During this formative period of life; Adolescents experience increasing levels of uncertainty and self-consciousness as they progress through the task of identity formation. It is greatly influenced by social interactions, especially interactions with peers.Children and adolescents with epilepsy are at increased risk for social problems, reduced social competence, poor social skills, and deficits in social communication compared to healthy children. Compared to youth with other chronic diseases, youth with epilepsy have higher rates of comorbid neurological disorders, academic failure, poor social skills, stigma, poor quality of life, and behavioral health problems (e.g., anxiety, depression). They often experience low quality of life because they feel unsafe and fear having a seizure in public. In a study aiming to investigate the factors affecting the level of social anxiety in epilepsy, it was concluded that social anxiety is independently associated with low quality of life. In a meta-analysis study; It was concluded that the motivational interviewing method applied by nurses increased the quality of life of individuals with chronic diseases. When the literature was examined, no study was found that addressed the motivational interviewing technique applied to the social anxiety and quality of life of adolescents with epilepsy. Motivational Interviewing Technique applied to adolescents with epilepsy; It is thought that it will be effective in reducing social anxiety and increasing the quality of life by enabling adolescents to become aware of their situation, get rid of the ambivalent (opposite emotional state) they experience, and take action to change.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-Not attending at least one of the interviewing
The Motivational Interviewing Technique Group (n=36) An equal number of patients will be classified by gender. Before the interview, each adolescent: Informed Consent Form, Personal Information Form, Social Anxiety Scale for Adolescents, Children's General Quality of Life Scale, and KINDL Epilepsy Quality of Life Module for Children will be applied. Interviews will be held in the training room next to the Child Neurology Polyclinic. In our study; The motivational interviewing technique will be applied to the experimental group individually by the researcher at 2-week intervals, including a preliminary interview and 6 motivational interview sessions. Each motivational interview will last approximately 40-50 minutes. One day before the motivational interview day, the experimental group will be informed by calling their registered phone numbers. The surveys will be re-administered after the end of the interview sessions. Surveys will be administered again after 1 month.
Other: The Motivational Interviewing Technique
No Intervention Group (n=36) Equal numbers of patients will be stratified according to gender. Adolescents without intervention; Patient Consent Form, Personal Information Form, Social Anxiety Scale in Adolescents, Child's General Quality of Life Scale, KINDL Epilepsy Quality of Life Module in Children will be applied. Routine follow-up and treatment will continue. The duration of the pre-interview and 6 motivational interviews will be calculated and the scales will be applied again.The surveys will be administered again after 1 month.
Motivational interviewing technique applied to adolescents with epilepsy; It is thought that it will be effective in reducing social anxiety and increasing the quality of life of adolesce.
"Social Anxiety Scale for Adolescents" [Time Frame: After the motivational interviewing technique]
A high score on the Social Anxiety Scale for Adolescents indicates high anxiety.
Time frame: 3 months
''KINDL Epilepsy Quality of Life Module for Children'' [Time Frame: After the motivational interviewing technique]
A high score on the KINDL Epilepsy Quality of Life Module for Children indicates good healthy quality of life.
Time frame: 3 months
"Children's General Quality of Life Scale'' [Time Frame: After the motivational interviewing technique]
A high score on the Children's General Quality of Life Scale for Children indicates good healthy quality of life.
Time frame: 3 months
"Social Anxiety Scale for Adolescents" [Time Frame: 1 month after the Motivational Interviewing Technique]
A high score on the Social Anxiety Scale for Adolescents indicates high anxiety.
Time frame: 1 months
''KINDL Epilepsy Quality of Life Module for Children'' [Time Frame: 1 month after the Motivational Interviewing Technique]
A high score on the KINDL Epilepsy Quality of Life Module for Children indicates good healthy quality of life.
Time frame: 1 months
"Children's General Quality of Life Scale" [Time Frame: 1 month after the Motivational Interviewing Technique]
A high score on the Children's General Quality of Life Scale for Children indicates good healthy quality of life.
Time frame: 1 months
Plan to share: No
Started Nov 2023 (actual). Primary completion is estimated for May 2024, 6 months after the start.
Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's planned 6 months is below that.
Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Izmir Katip Celebi University →